Session: SUN 163-194-Pituitary Disorders & Case Reports
Poster Board SUN-164
Case: A 40 year old male presented with 4 month history of lethargy, polyuria and polydipsia. Past history was unremarkable apart from an “eyelid” lump removed in 2010. The patient underwent hormonal assessment with basal hormones, an ITT and overnight water deprivation. He had panhypopituitarism and diabetes insipidus and commenced on hydrocortisone, thyroxine, oral dDAVP, GH and hCG (as he was seeking fertility). MRI pituitary demonstrated a homogeneous dumbbell shaped lesion 13.7mm in height, not compressing the optic chiasm, with florid enhancement post contrast. Pituitary biopsy showed eosinophils, macrophages, lymphocytes and occasional plasma cells, and a diagnosis of lymphocytic hypophysitis was made.
Five months later the patient complained of paraesthesia under the right eye. CT orbit revealed bilaterally enlarged infraorbital nerves. Nerve biopsy showed 40 IgG4+ plasma cells / HPF and ratio of IgG4+/ IgG+ plasma cells of >70% . Retrospective staining of the pituitary biopsy showed 70 IgG4+ plasma cells / HPF and ratio of IgG4+/ IgG+ plasma cells of >90% consistent with IgG4 lymphocytic hypophysitis. Serum IgG4 levels were markedly raised at 5.92 g/L (0.04-0.86). The patient was commenced on prednisolone 30mg/day. IgG4 levels reduced over the next 3 months to 1.72 g/L(0.04-0.86), but repeat MRI scan showed an enlarging pituitary mass with new optic nerve compression. Azathioprine 75mg bd was commenced whilst weaning prednisolone. Over the next 3 months, IgG4 levels normalised (0.58 g/L) and MRI scan showed 50% shrinkage of the pituitary mass. After 10 months of azathioprine the MRI showed a normal sized pituitary with improvement of the infraorbital nerve thickening. The patient remains only on thyroxine, testosterone and oral dDAVP. Serum IgG4 increased to 1.14 g/l, so azathioprine has been increased to 100mg bd.
Clinical Lesson: In the literature, all 12 reported cases of IgG4 lymphocytic hypophysitis treated with 30-50mg/day prednisolone demonstrated treatment response (1, 2). Our case is the first to demonstrate enlargement of the pituitary mass during glucocorticoid treatment, and that a switch to azathioprine resulted in disease control.
Nothing to Disclose: CC, CS, PM, AB, WJI
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters